Lens disorders in degenerative myopia. Treatment options
DOI: 10.32364/2311-7729-2023-23-4-6
M.G. Rabadanova1,2, J.G. Oganezova1, E.V. Kremkova1, M.M. Yakh'yaeva1
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2O.M. Filatov City Clinical Hospital No. 15, Moscow, Russian Federation
Cataracts are the leading cause of vision loss in patients over 50 years. In addition to senile cataracts, its earlier development due to various risk factors (for example, degenerative myopia characterized by lens opacity even in low myopia) is also an issue. This article discusses the pathogenesis of cataracts with a focus on oxidative stress, which is also important for myopia progression. The published and authors' data on the association between myopia and cataracts are addressed. The importance of early diagnosis of cataract in patients with myopia at the stage of lens suture compaction and its early radial and meridional opacities (that is possible with maximum mydriasis) is emphasized. Potential complex therapy with anti-cataract drops characterized by antioxidant effect is discussed as a pathogenetic approach to delay cataract progression in patients who (for various reasons) are not suitable for surgery. Recommendations for modifying the lifestyle to prevent cataract development are provided.
Keywords: degenerative myopia, myopic cataract, lens, oxidative stress, antioxidants, risk factors, drug treatment, pirenoxine.
For citation: Rabadanova M.G., Oganezova J.G., Kremkova E.V., Yakh'yaeva M.M. Lens disorders in degenerative myopia. Treatment options. Russian Journal of Clinical Ophthalmology. 2023;23(4):207–212 (in Russ.). DOI: 10.32364/2311-7729-2023-23-4-6.
About the authors:
Madina G. Rabadanova — C. Sc. (Med.), associate professor of the Academician A.P. Nesterov Department of Ophthalmology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ophthalmologist in the Laser Department, O.M. Filatov City Clinical Hospital No. 15; 23, Veshnyakovskaya str., Moscow, 111539, Russian Federation; ORCID iD 0000-0003-2847-3670.
Janna G. Oganezova — C. Sc. (Med.), associate professor of the Academician A.P. Nesterov Department of Ophthalmology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0002-4437-9070.
Elena V. Kremkova — Dr. Sc. (Med.), Professor, professor of the Academician A.P. Nesterov Department of Ophthalmology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation.
Mar'yana M. Yakh”yaeva — student of the 5th course of the Pediatric Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation.
Contact information: Janna G. Oganezova, e-mail: jannaogan@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 31.08.2023.
Revised 21.09.2023.
Accepted 12.10.2023.
2. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144–e160. DOI: 10.1016/S2214-109X(20)30489-7.
3. Midha N.K., Garg M.K., Kumar D. et al. Rapidly Developing Cataract in Young Adult Patients: Always a Matter for Further Evaluation. Cureus. 2021;13(8):e17312. DOI: 10.7759/cureus.17312.
4. Fraunfelder F.F.T., Fraunfelder F.R.W. Drug-Induced Ocular Side Effects: Clinical Ocular Toxicology. Elsevier Health Sciences; 2020.
5. Lehrer S., Rheinstein P.H. Marijuana smoking and cataract. J Fr Ophtalmol. 2022;45(3):267–271. DOI: 10.1016/j.jfo.2021.12.008.
6. Ковалевская М.А., Владимирова Ю.В., Филина Л.А., Кокорев В.Л. Современные концепции и перспективы воздействия на катарактогенез. Клиническая офтальмология. 2021;21(1):24–28. DOI: 10.32364/2311-7729-2021-21-1-24-28.5. [Kovalevskaya M.A., Vladimirova Yu.V., Filina L.A., Kokorev V.L. Current conceptions and promising tools to prevent cataractogenesis. Russian Journal of Clinical Ophthalmology. 2021;21(1):24–28 (in Russ.)]. DOI: 10.32364/2311-7729-2021-21-1-24-28.
7. Upaphong P., Thonusin C., Choovuthayakorn J. et al. The Possible Positive Mechanisms of Pirenoxine in Cataract Formation. Int J Mol Sci. 2022;23(16):9431. DOI: 10.3390/ijms23169431.
8. Holden B.A., Fricke T.R., Wilson D.A. et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036–1042. DOI: 10.1016/j.ophtha.2016.01.006.
9. Wang W., Xiang Y., Zhu L. et al. Myopia progression and associated factors of refractive status in children and adolescents in Tibet and Chongqing during the COVID-19 pandemic. Front Public Health. 2022;10:993728. DOI: 10.3389/fpubh.2022.993728.
10. Yang Z., Wang X., Zhang S. et al. Pediatric Myopia Progression During the COVID-19 Pandemic Home Quarantine and the Risk Factors: A Systematic Review and Meta-Analysis. Front Public Health. 2022;10:835449. DOI: 10.3389/fpubh.2022.835449.
11. Zhou W., Li Q., Chen H. et al. Trends of myopia development among primary and junior school students in the post-COVID-19 epidemic period. Front Public Health. 2022;10:970751. DOI: 10.3389/fpubh.2022.970751.
12. Németh J., Tapasztó B., Aclimandos W.A. et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2021;31(3):853–883. DOI: 10.1177/1120672121998960.
13. Landreneau J.R., Hesemann N.P., Cardonell M.A. Review on the Myopia Pandemic: Epidemiology, Risk Factors, and Prevention. Mo Med. 2021;118(2):156–163.
14. Bullimore M.A., Ritchey E.R., Shah S. et al. The Risks and Benefits of Myopia Control. Ophthalmology. 2021;128(11):1561–1579. DOI: 10.1016/j.ophtha.2021.04.032.
15. Zhu X., Du Y., Li D. et al. Aberrant TGF-β1 signaling activation by MAF underlies pathological lens growth in high myopia. Nat Commun. 2021;12(1):2102. DOI: 10.1038/s41467-021-22041-2.
16. Zhu X., Li D., Du Y. et al. DNA hypermethylation-mediated downregulation of antioxidant genes contributes to the early onset of cataracts in highly myopic eyes. Redox Biol. 2018;19:179–189. DOI: 10.1016/j.redox.2018.08.012.
17. Zhu X.J., Zhou P., Zhang K.K. et al. Epigenetic regulation of αA-crystallin in high myopia-induced dark nuclear cataract. PLoS One. 2013;8(12):e81900. DOI: 10.1371/journal.pone.0081900.
18. Haarman A.E.G., Enthoven C.A., Tideman J.W.L. et al. The Complications of Myopia: A Review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49. DOI: 10.1167/iovs.61.4.49.
19. Яхъяева М.М., Корсакова Е.И., Светличная С.В. Оценка состояния хрусталика у пациентов с осложненной миопией. В кн.: сб. тезисов XVIII Международной (XXVII Всероссийской) Пироговской научной медицинской конференции студентов и молодых ученых (Москва, 16 марта 2023 г.). М.: РНИМУ им. Н.И. Пирогова, 2023:32. [Yakh”yayeva M.M., Korsakova Ye.I., Svetlichnaya S.V. Assess the condition of the lens in patients with complicated myopia. In the collection of abstracts / XVIII International (XXVII All-Russian) Pirogov Scientific Medical Conference of Students and Young Scientists (Moscow, March 16, 2023). M.: RNIMU im. N.I. Pirogova, 2023:32 (in Russ.)].
20. Francisco B.M., Salvador M., Amparo N. Oxidative stress in myopia. Oxid Med Cell Longev. 2015;2015:750637. DOI: 10.1155/2015/750637.
21. Kanthan G.L., Mitchell P., Rochtchina E. et al. Myopia and the long-term incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2014;42(4):347–353. DOI: 10.1111/ceo.12206.
22. Du Y., Meng J., He W. et al. Challenges of refractive cataract surgery in the era of myopia epidemic: a mini-review. Front Med (Lausanne). 2023;10:1128818. DOI: 10.3389/fmed.2023.1128818.
23. Hoang Q.V., Chan X., Zhu X. et al. Editorial: Advances in Management and Treatment of High Myopia and Its Complications. Front Med (Lausanne). 2022;9:846540. DOI: 10.3389/fmed.2022.846540.
24. Shiels A., Hejtmancik J.F. Biology of Inherited Cataracts and Opportunities for Treatment. Annu Rev Vis Sci. 2019;5:123–149. DOI: 10.1146/annurev-vision-091517-034346.
25. Петров С.Ю., Козлова И.В., Полева Р.П. Катаракта: современный взгляд на консервативные подходы к лечению. Клиническая офтальмология. 2019;19(4):206–210. DOI: 10.32364/2311-7729-2019-19-4-206-210. [Petrov S.Yu., Kozlova I.V., Poleva R.P. Conservative treatment for cataract: state-of-the-art. Russian Journal of Clinical Ophthalmology. 2019;19(4):206–210 (in Russ.)]. DOI: 10.32364/2311-7729-2019-19-4-206-210.
26. Полунин Г.С., Макаров И.А., Бубнова И.А. Изучение терапевтической эффективности Каталина при возрастной катаракте (срок наблюдения 1 год). Клиническая офтальмология. 2012;12(3):110–114. [Polunin G.S., Makarov I.A., Bubnov I.A. Study of therapeutic efficiency of Catalin in patients with a senile cataract (1–year observation). Russian Journal of Clinical Ophthalmology. 2012;12(3):110–114 (in Russ.)].
27. Tsuneyoshi Y., Higuchi A., Negishi K., Tsubota K. Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy. Sci Rep. 2017;7(1):6819. DOI: 10.1038/s41598-017-07208-6.
28. Ильинская И.А., Копаев С.Ю. Возможности сохранения зрительных функций у пациентов, ожидающих плановое хирургическое лечение катаракты. Клиническая офтальмология. 2020;20(3):117–121. DOI: 10.32364/2311-7729-2020-20-3-117-121. [Il'inskaya I.A., Kopaev S.Yu. Maintenance of visual functions in patients with a scheduled cataract surgery. Russian Journal of Clinical Ophthalmology. 2020;20(3):117–121 (in Russ.)]. DOI: 10.32364/2311-7729-2020-20-3-117-121.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать